Li Kang Biomedical , Ltd. EBIT

Li Kang Biomedical , Ltd. (6242.TWO) currently reports a EBIT of $85M as of June 2026. That compares with $110M in the prior-year period — down 21.7% year over year. That is below the sector sector average of $2.6T. Use the charts on this page to explore Li Kang Biomedical , Ltd.'s EBIT history and peer comparisons.

Li Kang Biomedical , Ltd.'s EBIT decreased from $110M to $85M — a 21.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Li Kang Biomedical , Ltd.'s EBIT of $85M is lower than the its sector sector average of $2.6T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Li Kang Biomedical , Ltd. reported $85M in EBIT as of June 2026. That compares with $110M in the prior-year period — down 21.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $85M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.6T. From there, open related valuation or income-statement pages for Li Kang Biomedical , Ltd., and consider following 6242.TWO for alerts when major investors trade the stock.